A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease
Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H · 2000 · J Am Geriatr Soc 48:1566-1571
Reported findings and study design
After four weeks, ADAS-Cog improvement was reported in 82% with Cerebrolysin versus 31.6% with placebo. Global and MMSE ratings also favored treatment; daily-living scales did not.
Dose, route and schedule
Cerebrolysin 30 mL intravenously Monday–Friday for four weeks versus placebo. Historical study methods, not personal-use instructions.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-Cog improvement | 82% versus 31.6% | 4 weeks · p=0.02 for the ADAS-Cog comparison |
| Global improvement | 62% versus 22% | p=0.01 |
| MMSE improvement | 44% versus 17% | p=0.04 |
| Daily-living and depression scales | No significant between-group improvement in ADL, IADL or GDS |
Short trial; improved cognitive ratings did not translate into demonstrated ADL or IADL benefit. Rounded response percentages are retained as reported rather than converted to participant counts.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Short trial; improved cognitive ratings did not translate into demonstrated ADL or IADL benefit.
- Rounded response percentages are retained as reported rather than converted to participant counts.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Original journal report
Citation and original source
Original source: Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease J Am Geriatr Soc 48:1566-1571 2000.
Molekul research summary: https://molekul.io/research/placebo-11129744. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry